Improving clinical trial design in the precision psychiatry era


Lauren Liss PhD

Boehringer Ingelheim International GmbH

Disclosures

Full-time employee of Boehringer Ingelheim International GmbH


Psychiatry practitioners recognise a variety of inter-related drivers of change



Bubble size illustrates prevalence of topic among key opinion leaders in psychiatry

Markham T, Eade, D, Galimam L. Interviews with practitioners in the psychiatry field. October 2022, Lumanity.

Precision psychiatry: Taking individual variability into account






Developing treatments that can **target underlying neurobiological processes** is at the centre of this approach²

DSM-5, Diagnostic and Statistical Manual of Mental Disorders, 5th edition; MoA, mode of action.

1. Insel TR & Cuthbert BN. Science 2015;348:499–500; 2. Boehringer Ingelheim. Press Release. September 2020. Available at: https://www.boehringer-ingelheim.com/press-release/phase-ii-results-cognitive-impairment-schizophrenia.

Precision psychiatry is coming to the clinic: an example from an ongoing trial programme





A meta-analysis of neuroimaging studies supported the role of amygdala dysfunction across disorders, with behavioural alterations linked to abnormal amygdala activity and dysfunctional interaction with cortical regions¹

This precision psychiatry approach has potential clinical benefits: data-driven identification of subpopulations who are more likely to respond to the MoA of a given medication

BPD, borderline personality disorder; MDD, major depressive disorder; MoA, mode of action; PTSD, post-traumatic stress disorder.

1. Degasperi G, et al. Transl Psychiatry 2021;11:314; 2. Tang S, et al. EBioMedicine 2018;36:436–445; 3. Fenster RJ, et al. Nat Rev Neurosci 2018;19:535–551.